Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113187872> ?p ?o ?g. }
- W2113187872 endingPage "784" @default.
- W2113187872 startingPage "779" @default.
- W2113187872 abstract "Persistent variation in practice surrounds preoperative clopidogrel management at the time of vascular surgery. While some surgeons preferentially discontinue clopidogrel citing a perceived risk of perioperative bleeding, others will proceed with surgery in patients taking clopidogrel for an appropriate indication. The purpose of this study was to determine whether preoperative clopidogrel use was associated with significant bleeding complications during peripheral arterial surgery.We reviewed a prospective regional vascular surgery registry recorded by 66 surgeons from 15 centers in New England from 2003 to 2009. Preoperative clopidogrel use within 48 hours of surgery was analyzed among patients undergoing carotid endarterectomy (CEA), lower extremity bypass (LEB), endovascular abdominal aortic aneurysm repair (EVAR), and open abdominal aortic aneurysm repair (oAAA). Ruptured AAAs were excluded. Endpoints included postoperative bleeding requiring reoperation, as well as the incidence and volume of blood transfusion. Statistical analysis was performed using analysis of variance, Fisher exact, χ(2), and Wilcoxon rank-sum tests.Over the study interval, a total of 10,406 patients underwent surgery, including 5264 CEA, 2883 LEB, 1125 EVAR, and 1134 oAAA repair. Antiplatelet use among all patients varied, with 19% (n = 2010) taking no antiplatelet agents, 69% (n = 7132) taking aspirin (ASA) alone, 2.2% (n = 229) taking clopidogrel alone, and 9.7% (n = 1017) taking both ASA and clopidogrel. Clopidogrel alone or as dual antiplatelet therapy was most frequently used prior to CEA and least frequently prior to oAAA group (CEA 16.1%, LEB 9.0%, EVAR 6.5%, oAAA 5%). Reoperation for bleeding was not significantly different among patients based on antiplatelet regimen (none 1.5%, ASA 1.3%, clopidogrel 0.9%, ASA/clopidogrel 1.5%, P = .74). When analyzed by operation type, no difference in reoperation for bleeding was seen across antiplatelet regimens. There was also no difference in the incidence of transfusion among antiplatelet treatment groups (none 18%, ASA 17%, clopidogrel 0%, ASA/clopidogrel 24%, P = .1) and none when analyzed by individual operation type. Among patients who did require transfusion, there was no significant difference in the mean number of units of packed red blood cells required (none 0.7 units, ASA 0.5 units, clopidogrel 0 units, ASA/clopidogrel 0.6 units, P = .1) or when stratified by operation type.Patients undergoing peripheral arterial surgery in whom clopidogrel was continued either alone or as part of dual antiplatelet therapy did not have significant bleeding complications compared with patients taking no antiplatelet therapy or ASA alone at the time of surgery. These data suggest that clopidogrel can safely be continued preoperatively in patients with appropriate indications for its use, such as symptomatic carotid disease or recent drug-eluting coronary stents." @default.
- W2113187872 created "2016-06-24" @default.
- W2113187872 creator A5030045473 @default.
- W2113187872 creator A5040906595 @default.
- W2113187872 creator A5044493690 @default.
- W2113187872 creator A5045922184 @default.
- W2113187872 creator A5050102431 @default.
- W2113187872 creator A5053614501 @default.
- W2113187872 creator A5065001569 @default.
- W2113187872 creator A5090442172 @default.
- W2113187872 date "2011-09-01" @default.
- W2113187872 modified "2023-10-12" @default.
- W2113187872 title "Clopidogrel is not associated with major bleeding complications during peripheral arterial surgery" @default.
- W2113187872 cites W1596397105 @default.
- W2113187872 cites W1984396324 @default.
- W2113187872 cites W1991835721 @default.
- W2113187872 cites W2005401250 @default.
- W2113187872 cites W2007755521 @default.
- W2113187872 cites W2007819514 @default.
- W2113187872 cites W2040961609 @default.
- W2113187872 cites W2078050788 @default.
- W2113187872 cites W2079595856 @default.
- W2113187872 cites W2095680630 @default.
- W2113187872 cites W2111622726 @default.
- W2113187872 cites W2133064830 @default.
- W2113187872 cites W2144194629 @default.
- W2113187872 cites W2148895634 @default.
- W2113187872 cites W4205805944 @default.
- W2113187872 doi "https://doi.org/10.1016/j.jvs.2011.03.003" @default.
- W2113187872 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5292249" @default.
- W2113187872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21571492" @default.
- W2113187872 hasPublicationYear "2011" @default.
- W2113187872 type Work @default.
- W2113187872 sameAs 2113187872 @default.
- W2113187872 citedByCount "94" @default.
- W2113187872 countsByYear W21131878722012 @default.
- W2113187872 countsByYear W21131878722013 @default.
- W2113187872 countsByYear W21131878722014 @default.
- W2113187872 countsByYear W21131878722015 @default.
- W2113187872 countsByYear W21131878722016 @default.
- W2113187872 countsByYear W21131878722017 @default.
- W2113187872 countsByYear W21131878722018 @default.
- W2113187872 countsByYear W21131878722019 @default.
- W2113187872 countsByYear W21131878722020 @default.
- W2113187872 countsByYear W21131878722021 @default.
- W2113187872 countsByYear W21131878722022 @default.
- W2113187872 countsByYear W21131878722023 @default.
- W2113187872 crossrefType "journal-article" @default.
- W2113187872 hasAuthorship W2113187872A5030045473 @default.
- W2113187872 hasAuthorship W2113187872A5040906595 @default.
- W2113187872 hasAuthorship W2113187872A5044493690 @default.
- W2113187872 hasAuthorship W2113187872A5045922184 @default.
- W2113187872 hasAuthorship W2113187872A5050102431 @default.
- W2113187872 hasAuthorship W2113187872A5053614501 @default.
- W2113187872 hasAuthorship W2113187872A5065001569 @default.
- W2113187872 hasAuthorship W2113187872A5090442172 @default.
- W2113187872 hasBestOaLocation W21131878721 @default.
- W2113187872 hasConcept C126322002 @default.
- W2113187872 hasConcept C141071460 @default.
- W2113187872 hasConcept C2776098176 @default.
- W2113187872 hasConcept C2777628954 @default.
- W2113187872 hasConcept C2777849778 @default.
- W2113187872 hasConcept C2779993416 @default.
- W2113187872 hasConcept C2780120127 @default.
- W2113187872 hasConcept C2781068581 @default.
- W2113187872 hasConcept C2987047532 @default.
- W2113187872 hasConcept C31174226 @default.
- W2113187872 hasConcept C42219234 @default.
- W2113187872 hasConcept C71924100 @default.
- W2113187872 hasConceptScore W2113187872C126322002 @default.
- W2113187872 hasConceptScore W2113187872C141071460 @default.
- W2113187872 hasConceptScore W2113187872C2776098176 @default.
- W2113187872 hasConceptScore W2113187872C2777628954 @default.
- W2113187872 hasConceptScore W2113187872C2777849778 @default.
- W2113187872 hasConceptScore W2113187872C2779993416 @default.
- W2113187872 hasConceptScore W2113187872C2780120127 @default.
- W2113187872 hasConceptScore W2113187872C2781068581 @default.
- W2113187872 hasConceptScore W2113187872C2987047532 @default.
- W2113187872 hasConceptScore W2113187872C31174226 @default.
- W2113187872 hasConceptScore W2113187872C42219234 @default.
- W2113187872 hasConceptScore W2113187872C71924100 @default.
- W2113187872 hasIssue "3" @default.
- W2113187872 hasLocation W21131878721 @default.
- W2113187872 hasLocation W21131878722 @default.
- W2113187872 hasLocation W21131878723 @default.
- W2113187872 hasLocation W21131878724 @default.
- W2113187872 hasOpenAccess W2113187872 @default.
- W2113187872 hasPrimaryLocation W21131878721 @default.
- W2113187872 hasRelatedWork W1444716854 @default.
- W2113187872 hasRelatedWork W2009067400 @default.
- W2113187872 hasRelatedWork W2089408780 @default.
- W2113187872 hasRelatedWork W21747195 @default.
- W2113187872 hasRelatedWork W2298028530 @default.
- W2113187872 hasRelatedWork W2435339303 @default.
- W2113187872 hasRelatedWork W2597068225 @default.
- W2113187872 hasRelatedWork W2948003856 @default.
- W2113187872 hasRelatedWork W4280551504 @default.
- W2113187872 hasRelatedWork W2527719101 @default.